Using topiramate in patients with epilepsy: Practical aspects

被引:6
作者
Sander, JWAS [1 ]
机构
[1] UCL Natl Hosp Neurol & Neurosurg, Epilepsy Res Grp, Inst Neurol, London WC1N 3B6, England
关键词
D O I
10.1017/S0317167100034867
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Clinical trials are important in determining the relative efficacy and safety of a new antiepileptic drug (AED); however, experience acquired in clinical practice will eventually determine its position in the antiepileptic armamentarium. Topiramate (TPM), a new AED has been available in the United Kingdom since mid-1995 and a considerable number of patients have being treated. As a result of this experience, a number of changes have being made in the way TPM is used, particularly in the starting doses and titration rates. This seems to have improved patients' tolerability of treatment, an important consideration if a drug is to be used to its optimum level, in this article, practical tips for the use of TPM are given and these include starting doses, titration rates, options for managing side effects occurring early in treatment, advice concerning the withdrawal of concomitant AEDs and indications for discontinuation of TPM. The need for adequate patient counseling regarding potential side effects and expectations of treatment is also reviewed.
引用
收藏
页码:S16 / S18
页数:3
相关论文
共 11 条
[1]   Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures [J].
BenMenachem, E ;
Henriksen, O ;
Dam, M ;
Mikkelsen, M ;
Schmidt, D ;
Reid, S ;
Reife, R ;
Kramer, L ;
Pledger, G ;
Karim, R .
EPILEPSIA, 1996, 37 (06) :539-543
[2]   Preliminary open-label experience with topiramate in primary generalized seizures [J].
Biton, V .
EPILEPSIA, 1997, 38 :S42-S44
[3]  
BOURGEOIS BF, 1996, EPILEPSIA S2, V37, P14
[4]  
Espe-Lillo Joanne, 1995, Epilepsia, V36, P56
[5]   Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages [J].
Faught, E ;
Wilder, BJ ;
Ramsay, RE ;
Reife, RA ;
Kramer, LD ;
Pledger, GW ;
Karim, RM ;
Barr, A ;
Fischer, J ;
Bergen, D ;
Boor, D ;
Browne, T ;
Davenport, J ;
Dichter, M ;
Drake, M ;
Kuzniecky, R ;
Mamdani, M ;
McCutchen, C ;
Naritoku, D ;
Potolicchio, S ;
Ramani, V ;
Ramsay, R ;
Shinnar, S ;
So, E ;
Wilder, B .
NEUROLOGY, 1996, 46 (06) :1684-1690
[6]   Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages [J].
Privitera, M ;
Fincham, R ;
Penry, J ;
Reife, R ;
Kramer, L ;
Pledger, G ;
Karim, R ;
Bourgeois, B ;
Carter, G ;
Ferrendelli, J ;
Fincham, R ;
Fromm, G ;
Gallagher, B ;
Harner, R ;
Holmes, M ;
Leroy, R ;
Penry, J ;
Privitera, M ;
Rosenfeld, W ;
Rowan, A ;
Sackellares, JC ;
Smith, D ;
Willmore, L ;
Wyler, A .
NEUROLOGY, 1996, 46 (06) :1678-1683
[7]  
SACHDEO R, 1995, EPILEPSIA S3, V36, P151
[8]  
SHORVON SD, 1996, EPILEPSIA S2, V37, P18
[9]   The impact of new antiepileptic drugs on the prognosis of epilepsy: Seizure freedom should be the ultimate goal [J].
Walker, MC ;
Sander, JWAS .
NEUROLOGY, 1996, 46 (04) :912-914
[10]   Difficulties in extrapolating from clinical trial data to clinical practice: The case of antiepileptic drugs [J].
Walker, MC ;
Sander, JWAS .
NEUROLOGY, 1997, 49 (02) :333-337